Acceleron Hits Second Catalyst; Eight More SanaCurrents Catalysts Expected For 2Q 2020
Onconova Coverage suspended, Oragenics falls short in Phase II trial. The FDA last week approved Acceleron Pharma Inc. (NASDAQ:XLRN) luspatercept [...]
Onconova Coverage suspended, Oragenics falls short in Phase II trial. The FDA last week approved Acceleron Pharma Inc. (NASDAQ:XLRN) luspatercept [...]
vtv Therapeutics Inc. (NASDAQ:VTVT) Probability Sentiment SUMMARY Within the US population of 327 million, an [...]
The FDA approved the lead cancer drug from Blueprint Medicines (NASDAQ: BPMC) on January 9, sending the company’s shares to [...]
Shares of Apellis Pharmaceuticals (NASDAQ: APLS) shot up more than 20% January 7 after the company reported its drug, APL-2, [...]
I hope you had a great start to your new year. In 2020, we are resolving to aggressively hunt, actively [...]
I trust everyone enjoyed a good holiday season, which should have been more pleasurable by tallying yearly portfolio returns. The [...]
As 2019 winds to a close, SanaCurrents can look back at mostly good calls and a few disappointments on this [...]
SanaCurrents assigns a pivotal sentiment the FDA will approve the marketing of BIVIGAM, the Primary Humoral Immunodeficiency therapy from ADMA [...]